Cell Death and Disease (Oct 2022)

MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways

  • Shoji F. Kenji,
  • Keerthi Kurma,
  • Brigitte Collet,
  • Christelle Oblet,
  • Laure Debure,
  • Carmelo Di Primo,
  • Laëtitia Minder,
  • Franck Vérité,
  • Yannic Danger,
  • Mickael Jean,
  • Aubin Penna,
  • Nicolas Levoin,
  • Patrick Legembre

DOI
https://doi.org/10.1038/s41419-022-05352-0
Journal volume & issue
Vol. 13, no. 10
pp. 1 – 11

Abstract

Read online

Abstract CD95 is a death receptor that can promote oncogenesis through molecular mechanisms that are not fully elucidated. Although the mature CD95 membrane receptor is considered to start with the arginine at position 17 after elimination of the signal peptide, this receptor can also be cleaved by MMP7 upstream of its leucine at position 37. This post-translational modification occurs in cancer cells but also in normal cells such as peripheral blood leukocytes. The non-cleaved CD95 amino-terminal region consists in a disordered domain and its in silico reconstitution suggests that it might contribute to receptor aggregation and thereby, regulate the downstream death signaling pathways. In agreement with this molecular modeling analysis, the comparison of CD95-deficient cells reconstituted with full-length or N-terminally truncated CD95 reveals that the loss of the amino-terminal region of CD95 impairs the initial steps of the apoptotic signal while favoring the induction of pro-survival signals, including the PI3K and MAPK pathways.